• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    2/6/25 8:30:00 AM ET
    $EXAS
    $GE
    $GMED
    $XRAY
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology
    Get the next $EXAS alert in real time by email

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025.

    Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. Barber will be joining the Board's Science and Technology Committee and Mr. Scavilla will be joining the Board's Audit and Finance Committee.

    "We are pleased to welcome Mike and Dan, two proven leaders with skillsets that are additive to the expertise already represented on our Board and that will be extremely valuable as we continue to execute our transformation strategy," said Greg Lucier, Chairman of the Board. "The Board regularly reviews our composition against our strategic priorities, and we believe that adding broad healthcare experience, as well as deep innovation, technology, finance and operational capabilities, will help Dentsply Sirona realize our vision of transforming dentistry to improve oral health globally as the industry continues to evolve. As we move forward, the Board will continue to actively and regularly evaluate all opportunities to drive durable, profitable growth and enhanced shareholder value."

    Mr. Barber said, "With Dentsply Sirona's long heritage of innovation leadership in the global dental industry, I recognize the Company's tremendous potential, and I am eager to contribute to advance its mission. I appreciate the Board's confidence and look forward to working collaboratively with the rest of the Board and the management team to capitalize on the many opportunities ahead."

    Mr. Scavilla said, "I am honored to join the Board and continue to drive forward Dentsply Sirona's mission of transforming and advancing innovation. As a longtime executive in the healthcare industry, I look forward to bringing my insights and experience to support the Company's strategic growth."

    The Company also announced today that Dr. Dorothea Wenzel has informed the Board of her decision to resign, effective February 5, 2025, due to the increased demands of her recently announced chair nomination.

    "On behalf of the Board and management team, I want to thank Dorothea for her contributions to our Company," Mr. Lucier said. "The Board has benefitted greatly from her expertise and guidance, and we appreciate all she has done to help position Dentsply Sirona for the future."

    Dr. Wenzel added, "It has been an honor to serve on the Board over the last few years. I'm confident in the Board and management team's ability to deliver on the Company's strategy and drive long-term growth and profitability."

    With these changes, the Board has increased in size from 10 to 11 members. In the last two years, the Board has added four highly qualified members and will continue to refresh the Board to ensure the requisite skills to support the transformation of dentistry.

    About Michael Barber

    Mr. Barber has over 40 years of experience in executive positions with General Electric (NYSE:GE), featuring roles within operations, human capital, engineering, strategy, product management, and international P&L leadership. He has successfully launched transformational technologies and products to the market in the fields of diagnostic imaging and point-of-care technology. Mr. Barber also serves on the Board of Directors of Exact Sciences, Inc. (NASDAQ:EXAS) and as a member of the Executive Committee of the Green Bay Packers Football Club and the Board of Regents at the Milwaukee School of Engineering. He previously served on the Board of Directors of Catalent, Inc. He holds both a Bachelor of Science and an Honorary Doctorate in Electrical Engineering from the Milwaukee School of Engineering. He is a Member of the National Academy of Engineering (NAE) and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

    About Daniel Scavilla

    Mr. Scavilla has served as President and Chief Executive Officer of Globus Medical, Inc. (NYSE:GMED) since April 2022, leading Globus Medical's acquisition of NuVasive, Inc. and integrating the two organizations to create the second largest spine technology company in the world. Prior to that, Mr. Scavilla held various executive leadership positions at the company, including serving as its Chief Financial Officer. Prior to joining Globus Medical, Mr. Scavilla spent 28 years in increasing leadership roles within Johnson & Johnson, including roles across different businesses. Mr. Scavilla serves on Globus Medical's Board of Directors, and he previously served on the Board of Directors of Impulse Dynamics, a privately held medical technology company. Mr. Scavilla received a Bachelor of Science in Finance and Organizational Behavior from LaSalle University and a Master of Business Administration in International Management from Temple University.

    About Dentsply Sirona

    Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona's products provide innovative, high-quality, and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters is located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

    Contact Information

    Investors:

    Andrea Daley

    Vice President, Investor Relations

    +1-704-591-8631

    [email protected]

    Press:

    Marion Par-Weixlberger

    Vice President, Public Relations & Corporate Communications

    +43 676 848414588

    [email protected]



    Primary Logo

    Get the next $EXAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS
    $GE
    $GMED
    $XRAY

    CompanyDatePrice TargetRatingAnalyst
    GE Aerospace
    $GE
    2/20/2026$425.00Overweight
    Morgan Stanley
    DENTSPLY SIRONA Inc.
    $XRAY
    2/19/2026$17.00Neutral → Buy
    BofA Securities
    Globus Medical Inc.
    $GMED
    1/30/2026$112.00Hold → Buy
    Needham
    Globus Medical Inc.
    $GMED
    1/27/2026$110.00Buy
    TD Cowen
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    GE Aerospace
    $GE
    12/12/2025$386.00Buy
    Citigroup
    DENTSPLY SIRONA Inc.
    $XRAY
    12/9/2025$12.00Underweight
    Barclays
    More analyst ratings

    $EXAS
    $GE
    $GMED
    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $707,379 worth of shares (50,000 units at $14.15) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/26 7:12:19 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Forbes James D bought $67,345 worth of shares (5,000 units at $13.47) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/26 4:52:23 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Varon Leslie F bought $99,999 worth of shares (9,337 units at $10.71), increasing direct ownership by 19% to 57,343 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    11/25/25 5:26:33 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to the company's mission, enabling strong performance even during periods of change and complexity. "Our people are the heart of Exact Sciences," said Sarah Condella, executive vice president of human resources. "This recognition bel

    3/4/26 9:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026

    CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation

    3/3/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

    Amalgam Rx, Inc., Privia Health, and Exact Sciences Corp. highlight how coordinated, EHR-enabled patient outreach supported measurable screening impact at scale. Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ:PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ:EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rates to 84% in 2024, exceeding national benchmarks and surpassing the Natio

    3/3/26 10:00:00 AM ET
    $EXAS
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $EXAS
    $GE
    $GMED
    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on GE Aerospace with a new price target

    Morgan Stanley initiated coverage of GE Aerospace with a rating of Overweight and set a new price target of $425.00

    2/20/26 8:24:32 AM ET
    $GE
    Consumer Electronics/Appliances
    Technology

    Dentsply Sirona upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $17.00

    2/19/26 7:47:02 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Globus Medical upgraded by Needham with a new price target

    Needham upgraded Globus Medical from Hold to Buy and set a new price target of $112.00

    1/30/26 6:55:35 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    SEC Filings

    View All

    SEC Form 10-K filed by DENTSPLY SIRONA Inc.

    10-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    2/26/26 4:54:01 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    2/26/26 4:13:30 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Globus Medical Inc.

    10-K - GLOBUS MEDICAL INC (0001237831) (Filer)

    2/24/26 5:08:45 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Czerney Kevin was granted 13,690 shares, increasing direct ownership by 50% to 41,269 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/6/26 5:28:20 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SVP, CHRO Frohning Andrea L. was granted 26,786 shares, increasing direct ownership by 72% to 63,992 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/6/26 5:26:48 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    EVP, Chief Commercial Officer Denti Aldo Mariano Roberto was granted 59,524 shares (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/6/26 5:25:56 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

    CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu

    2/24/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

    News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend

    2/26/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Globus Medical Reports Fourth Quarter and Full Year 2025 Results

    AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for the quarter was $140.6 million.GAAP diluted earnings per share ("EPS") was $1.03, an increase of 442.6%. Non-GAAP diluted EPS was $1.28, an increase of 52.1%. Full Year

    2/24/26 4:15:00 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

    Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, resp

    2/13/26 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care